Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts

[1]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[2]  Yuki Togashi,et al.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.

[3]  F. Kaye.  Mutation-associated fusion cancer genes in solid tumors , 2009, Molecular Cancer Therapeutics.

[4]  Matthew L. Freedman,et al.  Analysis of the 10q11 Cancer Risk Locus Implicates MSMB and NCOA4 in Human Prostate Tumorigenesis , 2010, PLoS genetics.

[5]  S. Yeh,et al.  Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. , 2008, Cancer research.

[6]  J. R. Reeves,et al.  Prognostic Value of Prostate Secretory Protein of 94 Amino Acids and its Binding Protein after Radical Prostatectomy , 2006, Clinical Cancer Research.

[7]  Zhengxin Wang,et al.  Negative androgen-response elements mediate androgen-dependent transcriptional inhibition of TGF-β1 and CDK2 promoters in the prostate gland. , 2012, Journal of andrology.

[8]  W. Gerald,et al.  Association of Cysteine-Rich Secretory Protein 3 and β-Microseminoprotein with Outcome after Radical Prostatectomy , 2007, Clinical Cancer Research.

[9]  Baolin Wu,et al.  A role for MEIS1 in MLL-fusion gene leukemia. , 2009, Blood.

[10]  M. Rubin,et al.  SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. , 2009, Cancer research.

[11]  Ali Amin Al Olama,et al.  Multiple newly identified loci associated with prostate cancer susceptibility , 2008, Nature Genetics.

[12]  Francesca Demichelis,et al.  EML4-ALK fusion lung cancer: a rare acquired event. , 2008, Neoplasia.

[13]  F. Claessens,et al.  Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1alpha with multiple steroid receptors and identification of an internally deleted ELE1beta isoform. , 1999, Molecular endocrinology.

[14]  J. Thierry-Mieg,et al.  AceView: a comprehensive cDNA-supported gene and transcripts annotation , 2006, Genome Biology.

[15]  R. Sorek,et al.  Transcription-mediated gene fusion in the human genome. , 2005, Genome research.

[16]  J. Rowley,et al.  Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. Reymond,et al.  Tandem chimerism as a means to increase protein complexity in the human genome. , 2005, Genome research.

[18]  J. Rowley,et al.  Chromosome translocations: dangerous liaisons revisited , 2001, Nature Reviews Cancer.

[19]  W. Gerald,et al.  Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. , 2008, The American journal of pathology.

[20]  Stephen J. Chanock,et al.  Current status of genome-wide association studies in cancer , 2011, Human Genetics.

[21]  Charlotte N. Henrichsen,et al.  Prominent use of distal 5' transcription start sites and discovery of a large number of additional exons in ENCODE regions. , 2007, Genome research.

[22]  F. Claessens,et al.  The rules of DNA recognition by the androgen receptor. , 2010, Molecular endocrinology.

[23]  B. Johansson,et al.  Prevalence estimates of recurrent balanced cytogenetic aberrations and gene fusions in unselected patients with neoplastic disorders , 2005, Genes, chromosomes & cancer.

[24]  J. Sklar,et al.  A Neoplastic Gene Fusion Mimics Trans-Splicing of RNAs in Normal Human Cells , 2008, Science.

[25]  B. Johansson,et al.  Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer , 2004, Nature Genetics.

[26]  Thomas D. Wu,et al.  Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples , 2011, BMC Medical Genomics.

[27]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[28]  M. Santoro,et al.  Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. , 1994, Oncogene.

[29]  S. Yeh,et al.  Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[31]  E. Crawford,et al.  Epidemiology of prostate cancer. , 2003, Urology.

[32]  Mark Wade,et al.  Post-transcriptional exon shuffling events in humans can be evolutionarily conserved and abundant. , 2011, Genome research.

[33]  W. Willett,et al.  Multiple loci identified in a genome-wide association study of prostate cancer , 2008, Nature Genetics.

[34]  S. Weinstein,et al.  Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility , 2009, Proceedings of the National Academy of Sciences.

[35]  J. Carpten,et al.  Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. , 2009, Human molecular genetics.

[36]  Per Fernlund,et al.  Beta-microseminoprotein in serum correlates with the levels in seminal plasma of young, healthy males. , 2008, Journal of andrology.

[37]  T. Rabbitts,et al.  Chromosomal translocations in human cancer , 1994, Nature.

[38]  S. Fabre,et al.  Identification of a functional androgen response element in the promoter of the gene for the androgen-regulated aldose reductase-like protein specific to the mouse vas deferens. , 1994, The Journal of biological chemistry.

[39]  T A Gray,et al.  An imprinted, mammalian bicistronic transcript encodes two independent proteins. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Derek Y. Chiang,et al.  EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.

[41]  T. D. Schneider,et al.  Information analysis of human splice site mutations , 1998, Human mutation.

[42]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[43]  Toshiro Aigaki,et al.  Alternative trans‐splicing: a novel mode of pre‐mRNA processing , 2006, Biology of the cell.